Marine n-3 PUFA, heart rate variability and ventricular arrhythmias in patients on chronic dialysis: a cross-sectional study

The British Journal of Nutrition
Jesper M RantanenJ H Christensen

Abstract

Marine n-3 PUFA may improve autonomic dysfunction by an increase in heart rate variability (HRV) and may reduce the risk of malignant ventricular arrhythmias. Only a few smaller studies have examined such effects in patients on chronic dialysis, who often have autonomic dysfunction and a high risk of sudden cardiac death, which accounts for almost 30 % of all deaths. This cross-sectional study investigated the association between the plasma phospholipid content of n-3 PUFA and 24-h HRV or ventricular arrhythmias in patients on chronic dialysis. A 48-h Holter monitoring was performed on 169 patients on in-centre dialysis (83 %), home haemodialysis (10 %) or peritoneal dialysis (7 %) obtaining data on arrhythmias (n 152) and 24-h HRV (n 135). The mean overall HRV (standard deviation of normal intervals (SDNN)) was low and 71 % had a reduced overall HRV (SDNN<100 ms) indicating autonomic dysfunction. No significant associations between plasma phospholipid content of total marine n-3 PUFA, EPA (22 : 5n-3) or DHA (22 : 6n-3) and time-domain or frequency-domain HRV were detected in crude or adjusted linear regression analysis. However, a higher plasma phospholipid content of DHA was associated with a significantly lower proportion of...Continue Reading

References

Aug 26, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D K HathawayA O Gaber
Jun 26, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·J HayanoH Kawahara
Apr 12, 2002·The New England Journal of Medicine·Christine M AlbertJing Ma
Apr 30, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Nancy G KutnerXavier Aviles
Aug 7, 2002·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Barbara VillaCesare R Sirtori
Nov 4, 2005·Circulation·Alexander LeafUNKNOWN Fatty Acid Antiarrhythmia Trial Investigators
Feb 28, 2007·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Vanina SantiniSimona Frontoni
Jun 26, 2007·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·My SvenssonJeppe H Christensen
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·My SvenssonUNKNOWN OPACH Study Group
Jan 18, 2008·International Journal of Cardiology·Keiko OikawaHaruki Itoh
Jul 17, 2008·Seminars in Dialysis·Charles A HerzogRod Passman
Oct 23, 2008·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Allon N FriedmanBruce A Watkins
Nov 5, 2008·Cardiovascular Drugs and Therapy·Savina NodariLivio Dei Cas
Jan 27, 2009·International Journal of Cardiology·Masato NishimuraToshihiko Ono
Feb 11, 2009·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·J C LongeneckerM Omar
Sep 14, 2010·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Trine MadsenErik B Schmidt
Jan 5, 2011·American Journal of Nephrology·Kei HamazakiTomohito Hamazaki
May 3, 2012·JAMA : the Journal of the American Medical Association·Charmaine E LokUNKNOWN Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group
May 9, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Xiaoyan HuangJuan Jesús Carrero
Jun 23, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Mari SuzukiJunichiro Hayano
Nov 7, 2012·American Journal of Nephrology·Allon N FriedmanBruce A Watkins
Jun 4, 2013·Kidney International·Daniel Teta
Jan 11, 2014·Hemodialysis International·Yoshihiro TerashimaHidekuni Inadera
Jun 13, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Ivar A EideMy Svensson
Mar 25, 2016·Biomedizinische Technik. Biomedical Engineering·Débora Martins da SilvaRafael Pereira
Jun 14, 2016·Data in Brief·Tomi Akinyemiju, Justin Xavier Moore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.